Paraganglioma Market Size, Share, and Industry Analysis, By Origin (Head & Neck, Abdomen, Pelvis, and Others), By Disease Type (Carotid Paraganglioma, Cervical Paraganglioma, Jugular Paraganglioma, and Others), By Therapy (Chemotherapy, Targeted Therapy, and Others), By Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, and Online Pharmacies), and Regional Forecast 2025-2032

The global paraganglioma market is anticipated to witness significant growth driven by the soaring prevalence of chronic diseases. Paraganglioma is a rare type of neuroendocrine tumor that typically forms near the specific blood vessels and nerves located outside the adrenal glands, which are positioned on top of the kidneys. These glands play a crucial role in producing hormones that regulate numerous bodily functions.

Paraganglioma can manifest in the different areas of the body, including the head, neck, thorax, abdomen, or pelvis. These tumors are closely associated with pheochromocytomas, which are similar tumors originating from the adrenal glands. Both paragangliomas and pheochromocytomas can secrete hormones such as adrenaline and noradrenaline, resulting in symptoms such as hypertension, palpitations, and excessive sweating. Due to their potential hormone-secreting nature, the evaluation and management of paragangliomas and pheochromocytomas necessitate specialized medical attention.

• According to the National Cancer Institute (NCI), in February 2020, almost 35-50% of paragangliomas spread to other body parts.


• According to the National Cancer Institute (NCI), in February 2020, paraganglioma is a rare tumor with an estimated incidence of 2 cases per 1 million people and typically occurs in individuals aged 30 to 50.

Paraganglioma Market Driver

Increasing Prevalence of Paraganglioma to Fuel the Demand for Effective Therapeutics

The growing prevalence of chronic diseases, including cancers, heart disease, and diabetes, is a significant concern in today's society. This increase can be attributed to a variety of factors, such as the rising levels of obesity, widespread tobacco use, and shifts in dietary habits and alcohol consumption. Furthermore, these factors have led to a rise in the prevalence of cancers. Consequently, the escalating demand for effective treatments for various cancers has led to a notable surge in the demand for paraganglioma market. This trend is expected to continue driving substantial market growth in the foreseeable future.

• According to a March 2022 report by the National Center for Biotechnology Information (NCBI), the prevalence of chronic diseases in India was 21% overall, 17% in rural areas, and 29% in urban areas.

Request a Free sample to learn more about this report.

According to data published by the Global Cancer Observatory (GLOBOCAN) for the incidence of brain and central nervous system cancers for key regions, Asia accounts for the largest share of the case burden with an estimated 55.1% share of the total number of cases globally.

Paraganglioma Market Restraint

Lack of Regulatory Approvals for Therapies Specifically for Paraganglioma May Hamper Industry Expansion

One of the most critical hindrances for the growth of the global market is the limited regulatory approvals for therapies specifically created for the treatment of paraganglioma.

• As of 2024, the last approved drug for paraganglioma in the U.S., was the targeted radiopharmaceutical therapy of Azedra (iobenguane I 131) injection. This drug was approved for the adolescents and adults.

This dearth in terms of regulatory approvals for effective therapeutics leads to the adoption of off-label drugs for the treatment of paraganglioma. Furthermore, it may also lead to the noncompliance of treatment by patients due to the lack of effectiveness of the utilized therapeutics.

Paraganglioma Market Opportunity

Advancements in Technology for Paraganglioma Expected to Drive Growth in Coming Years

The ongoing progress of technology and innovation in the field of paraganglioma treatment has significantly elevated the standard of healthcare. This can be attributed to the extensive and ongoing research endeavors, as well as the focused efforts on drug development, which are integral parts of governmental initiatives aimed at raising awareness about the disease and its associated symptoms. Notably, the creation of novel tracers and the continuous technological advancements hold immense promise in enabling the evaluation of antitumor response and time dynamics within living organisms. Consequently, these developments are poised to further establish nuclear medicine as a crucial discipline in driving forward the principles of precision medicine.

• As of September 2024, according to data on clinical trials at ClinicalTrials.gov, several clinical trials were being conducted for paraganglioma treatment with pipeline candidates such as EO2401 by Enterome.

Segmentation

Key Insights

The report covers the following key insights:

• Prevalence of Paraganglioma, By Key Countries, 2023


• Overview: Regulatory & Reimbursement Scenario, By Key Countries/Region


• Pipeline Analysis, By Key Players


• Key Industry Developments (Mergers, Acquisitions, Partnerships, Launches)


• Impact of COVID-19 on Market

Analysis by Origin

By origin, the market is segmented into head & neck, abdomen, pelvis, and others.

The head and neck segment accounted for a significant market share in 2023. The growing burden of head & neck paraganglioma is driving the segment growth.

• According to the Multidisciplinary Digital Publishing Institute (MDPI), in May 2024, in Romania, the estimated percentage of head and neck paraganglioma was between 65% and 70%, which accounts for 0.7% of all tumors that occur at the head and neck level.

Analysis by Disease Type

Based on disease type, the market is segmented into carotid paraganglioma, cervical paraganglioma, jugular paraganglioma, and others.

The carotid paraganglioma segment held a significant market share in 2023. The growth of the segment is attributed to genetic factors that significantly influence the development of carotid paragangliomas. Mutations in specific genes, such as SDHB and SDHD, have been found to be associated with the occurrence of these tumors. The presence of these mutations can potentially serve as indicators for the development of carotid paragangliomas, highlighting the importance of effective diagnostics and treatment.

• According to PathologyOutlines, in January 2022, the annual incidence of paraganglioma was reported to be about 5 cases per million, with 500 to 1,600 cases reported per year in the U.S.

Analysis by Therapy

By therapy, the market is segmented into chemotherapy, targeted therapy, and others.

The targeted therapy segment held a significant market share in 2023. This is due to the presence of drugs approved by regulatory agencies under this segment. For instance, the radiopharmaceutical of Azedra (iobenguane I 131) injection is a targeted therapeutic, that is entirely composed of 131I-labeled MIBG (meta-iodobenzylguanidine).

• According to the National Cancer Institute, as of January 2023, some of the targeted therapies used for the treatment of paragangliomas include sunitinib, axitinib, and cabozantinib.

Analysis by Distribution Channel

Based on the distribution channel, the market is segmented into hospital pharmacies, drug stores & retail pharmacies, and online pharmacies.

The hospital pharmacies segment held a significant market share in 2023. The growth of the segment is attributed to the increasing prevalence of paraganglioma tumor and the preference of the patients toward getting diagnosed and treated both at the same place under experts’ treatment.

• According to an update published by Becker’s Hospital Review in December 2023, an estimated 123 cancer centers opened, expanded, or updated their affiliation in the U.S. in 2023

Furthermore, the online pharmacies segment held a considerable market share in 2023. The increasing preference of patients for buying medicines at the ease of their home and the increasing availability of prescription drugs in online pharmacies are driving the segment growth.

Regional Analysis

To gain extensive insights into the market, Request for Customization

By region, the market has been studied across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

North America held a significant market share in 2023. The segment growth can be attributed to the rising prevalence of chronic diseases. Moreover, companies such as Teva Pharmaceutical Industries Ltd. and Pfizer Inc., which are based in the U.S., also contribute to the increasing prevalence in this region.

• According to data published by Preventive Chronic Disease in February 2024, it was reported that an increasing proportion of people in America are dealing with multiple chronic conditions; 42% have 2 or more, and 12% have at least 5.

Europe held a substantial market share in 2023. Industry participants' growing efforts to develop therapies for chronic diseases and their increasing focus on obtaining regulatory approvals for increasing focus of  market players on effective novel treatment launches for paraganglioma are some of the factors driving market growth in the region.

The Asia Pacific market is expected to experience significant growth due to an increase in genetic mutations and unhealthy lifestyle choices, such as smoking and excessive alcohol consumption. This factor has been increasing the burden of tumor such as paraganglioma along with other diseases, fueling the demand for effective treatment for the condition.

• According to a report by Elsevier Ltd. in August 2024, Chinese patients appear to have a significant percentage of paraganglioma, with 25.1% of all cases in the Chinese population being located outside the adrenal gland.

Key Players Covered

The paraganglioma market consists of established companies such as Teva Pharmaceutical Industries Ltd., Pfizer Inc. among the key players. The report includes the profiles of the following key players:

• Teva Pharmaceuticals Industries Ltd. (U.S.)


• Pfizer Inc. (U.S.)


• Hikma Pharmaceuticals PLC  (U.S.)


• Amneal Pharmaceuticals LLC. (U.S.)


• Advacare Pharma (U.S.)


• Merck & Co., Inc. (U.S.)


• Actizapharma (India)


• Novartis AG (Switzerland)

Key Industry Developments

• In October 2023, Enterome announced updated results from the Phase 1/2 SPENCER trial of EO2401 in combination with nivolumab in adrenocortical carcinoma (ACC) and metastatic pheochromocytoma/paraganglioma (MPP), the two forms of adrenal tumors.


• In February 2021, Glenmark Pharmaceuticals, a research-led, global integrated pharmaceutical company, launched SUTIB, the generic version of sunitinib oral capsules, to treat kidney and neuroendocrine tumor cancer in India.